Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.
News
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as executive Vice President, Head of Research and Development
Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita
Top-Line Data Expected in Q4 2020 for Fast Track-Designated Program
Ride Health CEO Imran Cronk to Present at South by Southwest Alongside Leaders from American Heart Association and Ascension
Company also exhibiting cloud-based transportation coordination platform at RISE Medicare Advantage Summit and AMGA Annual Conference
Pillo Health Introduces Groundbreaking Automation of Multi-Dose Prescription Packaging
All-in-one pill packaging automation software streamlines pharmacies’ ability to fill multi-dose prescriptions that integrate into Pillo’s home health robot.
Pillo Health Launches Pillo Remotely, a Population Health Data and Device Manager to Improve Engagement & Visibility into In-Home Health Habits
Customizable device management interface offers increased control for healthcare professionals to deliver relevant, engaging communication to patients at scale.
This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO